Boehringer $LLY ; CAROLINA CVOT of Tradjenta met its primary endpoint of noninferiority compared with glimepiride httpswww.prnewswire.comnewsreleasesboehringeringelheimandlillyannouncethecarolinacardiovascularoutcometrialoftradjenta
Boehringer $LLY ; CAROLINA® CVOT of Tradjenta® met its primary endpoint of non-inferiority compared with glimepiride https://www.prnewswire.com/news-releases/boehringer-ingelheim-and-lilly-announce-the-carolina-cardiovascular-outcome-trial-of-tradjenta-
More From BioPortfolio on "Boehringer $LLY ; CAROLINA® CVOT of Tradjenta® met its primary endpoint of non-inferiority compared with glimepiride https://www.prnewswire.com/news-releases/boehringer-ingelheim-and-lilly-announce-the-carolina-cardiovascular-outcome-trial-of-tradjenta-"